In vitro evaluation of optimized liposomes for delivery of small interfering RNA

References

• Abu Lila AS, Ishida T, Kiwada H. (2009). Recent advances in tumor vasculature targeting using liposomal drug delivery systems. Expert Opin Drug Deliv 6:1297–309
   PubMed Web of Science ®Google Scholar
• Allen TM, Cullis PR. (2013). Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev 65:36–48
   PubMed Web of Science ®Google Scholar
• Bai S, Ahsan F. (2010). Inhalable liposomes of low molecular weight heparin for the treatment of venous thromboembolism. J Pharm Sci 99:4554–64
   PubMed Web of Science ®Google Scholar
• Bai S, Gupta V, Ahsan F. (2009). Cationic liposomes as carriers for aerosolized formulations of an anionic drug: safety and efficacy study. Eur J Pharm Sci 38:165–71
   PubMed Web of Science ®Google Scholar
• Bai S, Yang T, Abbruscato TJ, Ahsan F. (2008). Evaluation of human nasal RPMI 2650 cells grown at an air-liquid interface as a model for nasal drug transport studies. J Pharm Sci 97:1165–78
   PubMed Web of Science ®Google Scholar
• Chen Y, Sen J, Bathula SR, et al. (2009). Novel cationic lipid that delivers siRNA and enhances therapeutic effect in lung cancer cells. Mol Pharm 6:696–705
   PubMed Web of Science ®Google Scholar
• De Fougerolles A, Vornlocher HP, Maraganore J, Lieberman J. (2007). Interfering with disease: a progress report on siRNA-based therapeutics. Nat Rev Drug Discov 6:443–53
   PubMed Web of Science ®Google Scholar
• Ewert KK, Zidovska A, Ahmad A, et al. (2010). Cationic liposome-nucleic acid complexes for gene delivery and silencing: pathways and mechanisms for plasmid DNA and siRNA. Top Curr Chem 296:191–226
   PubMed Web of Science ®Google Scholar
• Filion MC, Phillips NC. (1997). Toxicity and immunomodulatory activity of liposomal vectors formulated with cationic lipids toward immune effector cells. Biochim Biophys Acta 1329:345–56
   PubMed Web of Science ®Google Scholar
• Gomes-da-Silva LC, Fonseca NA, Moura V, et al. (2012). Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges. Acc Chem Res 45:1163–71
   PubMed Web of Science ®Google Scholar
• Hobel S, Koburger I, John M, et al. (2010). Polyethylenimine/small interfering RNA-mediated knockdown of vascular endothelial growth factor in vivo exerts anti-tumor effects synergistically with Bevacizumab. J Gene Med 12:287–300
   PubMed Web of Science ®Google Scholar
• Hong YJ, Pyo CG, Kim JC. (2010). Liposomes incorporating hydrophobically modified silk fibroin: pH-dependent release. Int J Biol Macromol 47:635–9
   PubMed Web of Science ®Google Scholar
• Kanasty R, Dorkin JR, Vegas A, Anderson D. (2013). Delivery materials for siRNA therapeutics. Nat Mater 12:967–77
   PubMed Web of Science ®Google Scholar
• Kim SH, Jeong JH, Lee SH, et al. (2006). PEG conjugated VEGF siRNA for anti-angiogenic gene therapy. J Control Release 116:123–9
   PubMed Web of Science ®Google Scholar
• Kubowicz P, Zelaszczyk D, Pekala E. (2013). RNAi in clinical studies. Curr Med Chem 20:1801–16
   PubMed Web of Science ®Google Scholar
• Mikhaylova M, Stasinopoulos I, Kato Y, et al. (2009). Imaging of cationic multifunctional liposome-mediated delivery of COX-2 siRNA. Cancer Gene Ther 16:217–26
   PubMed Web of Science ®Google Scholar
• Moghimi SM, Hunter AC, Murray JC. (2001). Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev 53:283–318
   PubMed Web of Science ®Google Scholar
• Mu C, Dave N, Hu J, et al. (2013). Solubilization of flurbiprofen into aptamer-modified PEG-PLA micelles for targeted delivery to brain-derived endothelial cells in vitro. J Microencapsul 30:701–8
   PubMed Web of Science ®Google Scholar
• Ni X, Castanares M, Mukherjee A, Lupold SE. (2011). Nucleic acid aptamers: clinical applications and promising new horizons. Curr Med Chem 18:4206–14
   PubMed Web of Science ®Google Scholar
• Rapisarda A, Melillo G. (2012). Role of the VEGF/VEGFR axis in cancer biology and therapy. Adv Cancer Res 114:237–67
   PubMed Web of Science ®Google Scholar
• Schiffelers RM, Ansari A, Xu J, et al. (2004). Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res 32:e149–59
   PubMed Web of Science ®Google Scholar
• Schroeder A, Levins CG, Cortez C, et al. (2010). Lipid-based nanotherapeutics for siRNA delivery. J Intern Med 267:9–21
   PubMed Web of Science ®Google Scholar
• Shibuya M. (2011). Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: a crucial target for anti- and pro-angiogenic therapies. Genes Cancer 2:1097–105
   PubMedGoogle Scholar
• Sitohy B, Nagy JA, Dvorak HF. (2012). Anti-VEGF/VEGFR therapy for cancer: reassessing the target. Cancer Res 72:1909–14
   PubMed Web of Science ®Google Scholar
• Takahashi S. (2011). Vascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy. Biol Pharm Bull 34:1785–8
   PubMed Web of Science ®Google Scholar
• Torchilin VP. (2005). Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 4:145–60
   PubMed Web of Science ®Google Scholar
• Van de Water FM, Boerman OC, Wouterse AC, et al. (2006). Intravenously administered short interfering RNA accumulates in the kidney and selectively suppresses gene function in renal proximal tubules. Drug Metab Dispos 34:1393–7
   PubMed Web of Science ®Google Scholar
• Whitehead KA, Langer R, Anderson DG. (2009). Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov 8:129–38
   PubMed Web of Science ®Google Scholar
• Yang S, Chen Y, Ahmadie R, Ho EA. (2013). Advancements in the field of intravaginal siRNA delivery. J Control Release 167:29–39
   PubMed Web of Science ®Google Scholar
• Yang T, Nyiawung D, Silber A, et al. (2012). Comparative studies on chitosan and polylactic-co-glycolic acid incorporated nanoparticles of low molecular weight heparin. AAPS PharmSciTech 13:1309–18
   PubMed Web of Science ®Google Scholar
• Yuan X, Shah BA, Kotadia NK, et al. (2010). The development and mechanism studies of cationic chitosan-modified biodegradable PLGA nanoparticles for efficient siRNA drug delivery. Pharm Res 27:1285–95
   PubMed Web of Science ®Google Scholar